Elena Lomonosova

Elena Lomonosova

Auto-generated profile, based on publicly available information

Elena Lomonosova

Washington University School of Medicine in St. Louis

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
Purpose: To determine the ability of RAD51 foci to predict platinum chemotherapy response in high-grade serous ovarian cancer (HGSOC) patient-derived samples. Experimental Design: RAD51 and γH2AX nuclear foci were evaluated by immunofluorescence in HGSOC patient-derived cell lines (n = 5), organoids (n = 11), and formalin-fixed, paraffin-embedded tumor samples (discovery n = 31, validation n = 148). Samples were defined as RAD51-High if >10% of geminin-positive cells had ≥5 RAD51 foci. Associations between RAD51 scores, platinum chemotherapy response, and survival were evaluated. Results: RAD51 scores correlated with in vitro response to platinum chemotherapy in established and primary ovarian cancer cell lines (Pearson r = 0.96, P = 0.01). Organoids from platinum-nonresponsive tumors had significantly higher RAD51 scores than those from platinum-responsive tumors (P < 0.001). In a discovery cohort, RAD51-Low tumors were more likely to have a pathologic complete response (RR, 5.28; P < 0.001) and to be platinum-sensitive (RR, ∞; P = 0.05). The RAD51 score was predictive of chemotherapy response score [AUC, 0.90; 95% confidence interval (CI), 0.78–1.0; P < 0.001). A novel automatic quantification system accurately reflected the manual assay (92%). In a validation cohort, RAD51-Low tumors were more likely to be platinum-sensitive (RR, ∞; P < 0.001) than RAD51-High tumors. Moreover, RAD51-Low status predicted platinum sensitivity with 100% positive predictive value and was associated with better progression-free (HR, 0.53; 95% CI, 0.33–0.85; P < 0.001) and overall survival (HR, 0.43; 95% CI, 0.25–0.75; P = 0.003) than RAD51-High status. Conclusions: RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.

1 August 2023 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
ASAngela M. Schab
Angela M. Schab
MGMolly M. Greenwade
Molly M. Greenwade
ESElizabeth Stock
Elizabeth Stock
ELElena Lomonosova
Elena Lomonosova
KCKevin Cho
Kevin Cho
KFKatherine Fuh
Katherine Fuh
Ovarian cancer is the leading cause of gynecologic cancer–related deaths. The propensity for metastasis within the peritoneal cavity is a driving factor for the poor outcomes associated with this disease, but there is currently no effective therapy targeting metastasis. In this study, we investigate the contribution of stromal cells to ovarian cancer metastasis and identify normal stromal cell expression of the collagen receptor, discoidin domain receptor 2 (DDR2), that acts to facilitate ovarian cancer metastasis. In vivo, global genetic inactivation of Ddr2 impairs the ability of Ddr2-expressing syngeneic ovarian cancer cells to spread throughout the peritoneal cavity. Specifically, DDR2 expression in mesothelial cells lining the peritoneal cavity facilitates tumor cell attachment and clearance. Subsequently, omentum fibroblast expression of DDR2 promotes tumor cell invasion. Mechanistically, we find DDR2-expressing fibroblasts are more energetically active, such that DDR2 regulates glycolysis through AKT/SNAI1 leading to suppressed fructose-1,6-bisphosphatase and increased hexokinase activity, a key glycolytic enzyme. Upon inhibition of DDR2, we find decreased protein synthesis and secretion. Consequently, when DDR2 is inhibited, there is reduction in secreted extracellular matrix proteins important for metastasis. Specifically, we find that fibroblast DDR2 inhibition leads to decreased secretion of the collagen crosslinker, LOXL2. Adding back LOXL2 to DDR2 deficient fibroblasts rescues the ability of tumor cells to invade. Overall, our results suggest that stromal cell expression of DDR2 is an important mediator of ovarian cancer metastasis. Implications: DDR2 is highly expressed by stromal cells in ovarian cancer that can mediate metastasis and is a potential therapeutic target in ovarian cancer.

25 November 2025
Verified
Other
Open access
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity

25 November 2025
Verified
Other
Open access
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
Patient characteristics of FFPE validation cohort

5 July 2023
Verified
Other
Open access
PDF file
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids

5 July 2023
Verified
Other
Open access
PDF file
ACAmanda J. Compadre
Amanda J. Compadre
LBLillian N. van Biljon
Lillian N. van Biljon
MVMark C. Valentine
Mark C. Valentine
ALAlba Llop-Guevara
Alba Llop-Guevara
EGEmily Graham
Emily Graham
MMMary Margaret Mullen
Mary Margaret Mullen
Patient characteristics of patient-derived ovarian cancer cells